Veru (NASDAQ:VERU) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Veru (NASDAQ:VERU - Get Free Report) announced its earnings results on Thursday. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01, Zacks reports. Veru had a negative return on equity of 92.88% and a negative net margin of 223.85%.

Veru Price Performance

VERU traded up $0.02 on Monday, hitting $0.54. The company had a trading volume of 1,855,548 shares, compared to its average volume of 6,253,218. The firm has a market capitalization of $79.24 million, a P/E ratio of -1.93 and a beta of -0.54. The stock has a fifty day simple moving average of $0.71 and a 200-day simple moving average of $0.76. Veru has a 52-week low of $0.40 and a 52-week high of $1.92.

Wall Street Analyst Weigh In

VERU has been the topic of several research reports. HC Wainwright restated a "buy" rating and set a $3.00 price objective on shares of Veru in a report on Thursday, January 2nd. Oppenheimer reiterated an "outperform" rating and issued a $5.00 target price on shares of Veru in a research note on Tuesday, November 5th.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.